1	Thalidomide	Thalidomide	B-NP	NN	O	3	NMOD	-1
2	and	and	I-NP	CC	O	3	NMOD	-1
3	angiostatin	angiostatin	I-NP	NN	O	4	SUB	-1
4	inhibit	inhibit	B-VP	VBP	O	0	ROOT	18	inhibit
5	tumor	tumor	B-NP	NN	O	6	NMOD	-1
6	growth	growth	I-NP	NN	O	4	OBJ	4	growth
7	in	in	B-PP	IN	O	4	VMOD	-1
8	a	a	B-NP	DT	O	11	NMOD	-1
9	murine	murine	I-NP	JJ	O	11	NMOD	-1
10	xenograft	xenograft	I-NP	NN	O	11	NMOD	-1
11	model	model	I-NP	NN	O	7	PMOD	-1
12	of	of	B-PP	IN	O	11	NMOD	-1
13	human	human	B-NP	JJ	O	15	NMOD	-1
14	cervical	cervical	I-NP	JJ	O	15	NMOD	-1
15	cancer	cancer	I-NP	NN	O	12	PMOD	-1
16	.	.	O	.	O	4	P	-1

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	To	To	B-VP	TO	O	4	VMOD	-1
4	determine	determine	I-VP	VB	O	1	NMOD	-1
5	the	the	B-NP	DT	O	6	NMOD	-1
6	impact	impact	I-NP	NN	O	4	OBJ	0
7	of	of	B-PP	IN	O	6	NMOD	-1
8	thalidomide	thalidomide	B-NP	NN	O	10	NMOD	-1
9	and	and	I-NP	CC	O	10	NMOD	-1
10	angiostatin	angiostatin	I-NP	NN	O	7	PMOD	-1
11	on	on	B-PP	IN	O	6	NMOD	-1
12	tumor	tumor	B-NP	NN	O	13	NMOD	-1
13	growth	growth	I-NP	NN	O	18	NMOD	4	growth
14	,	,	O	,	O	18	P	-1
15	angiogenesis	angiogenesis	B-NP	NN	O	18	NMOD	3	angiogenesis
16	,	,	O	,	O	18	P	-1
17	and	and	O	CC	O	18	NMOD	-1
18	apoptosis	apoptosis	B-NP	NN	O	11	PMOD	5	apoptosis
19	in	in	B-PP	IN	O	18	NMOD	-1
20	a	a	B-NP	DT	O	22	NMOD	-1
21	xenograft	xenograft	I-NP	NN	O	22	NMOD	-1
22	model	model	I-NP	NN	O	19	PMOD	-1
23	of	of	B-PP	IN	O	22	NMOD	-1
24	cervical	cervical	B-NP	JJ	O	25	NMOD	-1
25	cancer	cancer	I-NP	NN	O	23	PMOD	-1
26	.	.	O	.	O	4	P	-1

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	Human	Human	B-NP	JJ	B-cell_type	6	NMOD	-1
4	umbilical	umbilical	I-NP	JJ	I-cell_type	6	NMOD	-1
5	endothelial	endothelial	I-NP	JJ	I-cell_type	6	NMOD	-1
6	cells	cell	I-NP	NNS	I-cell_type	7	SUB	-1
7	were	be	B-VP	VBD	O	1	NMOD	-1
8	treated	treat	I-VP	VBN	O	7	VC	19	treated
9	with	with	B-PP	IN	O	8	VMOD	-1
10	angiostatin	angiostatin	B-NP	NN	O	12	NMOD	-1
11	or	or	I-NP	CC	O	12	NMOD	-1
12	thalidomide	thalidomide	I-NP	NN	O	15	NMOD	-1
13	and	and	O	CC	O	15	NMOD	-1
14	bFGF-induced	bFGF-induced	B-NP	JJ	O	15	NMOD	-1
15	proliferation	proliferation	I-NP	NN	O	9	PMOD	0
16	was	be	B-VP	VBD	O	7	VMOD	-1
17	assessed	assess	I-VP	VBN	O	16	VC	-1
18	with	with	B-PP	IN	O	17	VMOD	-1
19	the	the	B-NP	DT	O	21	NMOD	-1
20	MTT	MTT	I-NP	NN	O	21	NMOD	-1
21	assay	assay	I-NP	NN	O	18	PMOD	-1
22	.	.	O	.	O	1	P	-1

1	Human	Human	B-NP	JJ	B-cell_type	4	NMOD	-1
2	cervical	cervical	I-NP	JJ	I-cell_type	4	NMOD	-1
3	cancer	cancer	I-NP	NN	I-cell_type	4	NMOD	-1
4	cells	cell	I-NP	NNS	I-cell_type	10	SUB	-1
5	(	(	O	(	O	9	DEP	-1
6	CaSki	CaSki	B-NP	NNP	O	8	NMOD	-1
7	and	and	I-NP	CC	O	8	NMOD	-1
8	SiHa	SiHa	I-NP	NNP	O	9	DEP	-1
9	)	)	O	)	O	4	NMOD	-1
10	were	be	B-VP	VBD	O	0	ROOT	-1
11	injected	inject	I-VP	VBN	O	10	VC	19	injected
12	into	into	B-PP	IN	O	11	VMOD	-1
13	the	the	B-NP	DT	O	14	NMOD	-1
14	flanks	flank	I-NP	NNS	O	12	PMOD	-1
15	of	of	B-PP	IN	O	14	NMOD	-1
16	nude	nude	B-NP	JJ	O	17	NMOD	-1
17	mice	mouse	I-NP	NNS	O	15	PMOD	-1
18	.	.	O	.	O	10	P	-1

1	After	After	B-SBAR	IN	O	6	VMOD	-1
2	tumors	tumor	B-NP	NNS	O	3	SUB	-1
3	developed	develop	B-VP	VBD	O	1	DEP	2	developed
4	,	,	O	,	O	6	P	-1
5	mice	mouse	B-NP	NNS	O	6	SUB	-1
6	were	be	B-VP	VBD	O	0	ROOT	-1
7	treated	treat	I-VP	VBN	O	6	VC	19	treated
8	with	with	B-PP	IN	O	7	VMOD	-1
9	angiostatin	angiostatin	B-NP	NN	O	11	NMOD	-1
10	20	20	I-NP	CD	O	11	NMOD	-1
11	mg/kg/day	mg/kg/day	I-NP	NN	O	8	PMOD	-1
12	or	or	O	CC	O	7	VMOD	-1
13	thalidomide	thalidomide	B-ADVP	IN	O	7	VMOD	-1
14	200	200	B-NP	CD	O	15	NMOD	-1
15	mg/kg/day	mg/kg/day	I-NP	NN	O	13	PMOD	-1
16	for	for	B-PP	IN	O	7	VMOD	-1
17	30	30	B-NP	CD	O	18	NMOD	-1
18	days	day	I-NP	NNS	O	16	PMOD	-1
19	.	.	O	.	O	6	P	-1

1	Fractional	Fractional	B-NP	JJ	O	3	NMOD	-1
2	tumor	tumor	I-NP	NN	O	3	NMOD	-1
3	growth	growth	I-NP	NN	O	4	SUB	4	growth
4	was	be	B-VP	VBD	O	11	VMOD	-1
5	determined	determine	I-VP	VBN	O	4	VC	-1
6	and	and	O	CC	O	11	VMOD	-1
7	immunohistochemical	immunohistochemical	B-NP	JJ	O	8	NMOD	-1
8	analysis	analysis	I-NP	NN	O	11	SUB	-1
9	of	of	B-PP	IN	O	8	NMOD	-1
10	tumors	tumor	B-NP	NNS	O	9	PMOD	-1
11	was	be	B-VP	VBD	O	0	ROOT	-1
12	used	use	I-VP	VBN	O	11	VC	0
13	to	to	B-VP	TO	O	14	VMOD	-1
14	determine	determine	I-VP	VB	O	12	VMOD	-1
15	degree	degree	B-NP	NN	O	14	OBJ	-1
16	of	of	B-PP	IN	O	15	NMOD	-1
17	angiogenesis	angiogenesis	B-NP	NN	O	16	PMOD	3	angiogenesis
18	.	.	O	.	O	11	P	-1

1	TUNEL	TUNEL	B-NP	NN	O	2	NMOD	-1
2	assay	assay	I-NP	NN	O	3	SUB	-1
3	was	be	B-VP	VBD	O	0	ROOT	-1
4	used	use	I-VP	VBN	O	3	VC	0
5	to	to	B-VP	TO	O	6	VMOD	-1
6	assess	assess	I-VP	VB	O	4	VMOD	-1
7	apoptosis	apoptosis	B-NP	NN	O	6	OBJ	0
8	.	.	O	.	O	3	P	-1

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	-1
3	Angiostatin	Angiostatin	B-NP	NN	O	4	SUB	-1
4	inhibited	inhibit	B-VP	VBD	O	1	NMOD	18	inhibited
5	endothelial	endothelial	B-NP	JJ	B-cell_type	7	NMOD	-1
6	cell	cell	I-NP	NN	I-cell_type	7	NMOD	-1
7	proliferation	proliferation	I-NP	NN	O	4	OBJ	1	proliferation
8	by	by	B-PP	IN	O	4	VMOD	-1
9	50-60	50-60	B-NP	CD	O	10	NMOD	-1
10	%	%	I-NP	NN	O	8	PMOD	-1
11	.	.	O	.	O	1	P	-1

1	Thalidomide	Thalidomide	B-NP	NN	O	2	SUB	-1
2	had	have	B-VP	VBD	O	0	ROOT	-1
3	no	no	B-NP	DT	O	5	NMOD	-1
4	direct	direct	I-NP	JJ	O	5	NMOD	-1
5	effect	effect	I-NP	NN	O	2	OBJ	0
6	on	on	B-PP	IN	O	2	VMOD	-1
7	endothelial	endothelial	B-NP	JJ	B-cell_type	8	NMOD	-1
8	cells	cell	I-NP	NNS	I-cell_type	6	PMOD	-1
9	.	.	O	.	O	2	P	-1

1	Angiostatin	Angiostatin	B-NP	NN	O	3	NMOD	-1
2	and	and	I-NP	CC	O	3	NMOD	-1
3	thalidomide	thalidomide	I-NP	NN	O	0	ROOT	-1
4	both	both	B-NP	DT	O	3	NMOD	-1
5	inhibited	inhibit	B-VP	VBD	O	4	SBAR	18	inhibited
6	tumor	tumor	B-NP	NN	O	7	NMOD	-1
7	growth	growth	I-NP	NN	O	5	OBJ	4	growth
8	by	by	B-PP	IN	O	5	VMOD	-1
9	about	about	B-NP	RB	O	11	NMOD	-1
10	55	55	I-NP	CD	O	9	AMOD	-1
11	%	%	I-NP	NN	O	8	PMOD	-1
12	.	.	O	.	O	3	P	-1

1	We	We	B-NP	PRP	O	2	SUB	-1
2	found	find	B-VP	VBD	O	0	ROOT	0
3	no	no	B-NP	DT	O	7	NMOD	-1
4	additive	additive	I-NP	JJ	O	7	NMOD	-1
5	or	or	I-NP	CC	O	7	NMOD	-1
6	synergistic	synergistic	I-NP	JJ	O	7	NMOD	-1
7	effect	effect	I-NP	NN	O	2	OBJ	0
8	when	when	B-ADVP	WRB	O	2	VMOD	-1
9	the	the	B-NP	DT	O	11	NMOD	-1
10	two	two	I-NP	CD	O	11	NMOD	-1
11	agents	agent	I-NP	NNS	O	12	SUB	-1
12	were	be	B-VP	VBD	O	8	SBAR	-1
13	combined	combine	I-VP	VBN	O	12	VC	-1
14	.	.	O	.	O	2	P	-1

1	Both	Both	B-NP	DT	O	2	NMOD	-1
2	agents	agent	I-NP	NNS	O	3	SUB	-1
3	inhibited	inhibit	B-VP	VBD	O	0	ROOT	18	inhibited
4	angiogenesis	angiogenesis	B-NP	NN	O	3	OBJ	3	angiogenesis
5	and	and	O	CC	O	3	VMOD	-1
6	induced	induce	B-VP	VBD	O	3	VMOD	0
7	apoptosis	apoptosis	B-NP	NN	O	6	OBJ	0
8	when	when	B-ADVP	WRB	O	3	VMOD	-1
9	compared	compare	B-VP	VBN	O	8	SBAR	-1
10	to	to	B-PP	TO	O	9	VMOD	-1
11	tumors	tumor	B-NP	NNS	O	10	PMOD	-1
12	from	from	B-PP	IN	O	11	NMOD	-1
13	control	control	B-NP	NN	O	14	NMOD	0
14	animals	animal	I-NP	NNS	O	12	PMOD	-1
15	.	.	O	.	O	3	P	-1

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	Angiostatin	Angiostatin	B-NP	NN	O	5	NMOD	-1
4	and	and	I-NP	CC	O	5	NMOD	-1
5	thalidomide	thalidomide	I-NP	NN	O	6	SUB	-1
6	inhibit	inhibit	B-VP	VBP	O	1	NMOD	18	inhibit
7	tumor	tumor	B-NP	NN	O	8	NMOD	-1
8	growth	growth	I-NP	NN	O	13	SUB	4	growth
9	,	,	O	,	O	13	P	-1
10	angiogenesis	angiogenesis	B-NP	NN	O	13	SUB	3	angiogenesis
11	,	,	O	,	O	13	P	-1
12	and	and	O	CC	O	13	VMOD	-1
13	induce	induce	B-VP	VBP	O	6	VMOD	17	induce
14	apoptosis	apoptosis	B-NP	NN	O	13	OBJ	5	apoptosis
15	in	in	B-PP	IN	O	13	VMOD	-1
16	this	this	B-NP	DT	O	18	NMOD	-1
17	xenograft	xenograft	I-NP	NN	O	18	NMOD	-1
18	model	model	I-NP	NN	O	15	PMOD	-1
19	of	of	B-PP	IN	O	18	NMOD	-1
20	cervical	cervical	B-NP	JJ	O	21	NMOD	-1
21	cancer	cancer	I-NP	NN	O	19	PMOD	-1
22	.	.	O	.	O	1	P	-1

